Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Ben Taub General Hospital — Houston, Texas
- UT MD Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Texas: - Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology-Northeast Texas — Allen, Texas
- Texas Oncology-West Texas — Amarillo, Texas
- Texas Oncology - DFW — Arlington, Texas
- The Center for Cancer and Blood Disorders — Arlington, Texas
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Texas: - Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology - Northeast Texas — Allen, Texas
- Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - DFW — Arlington, Texas
- Texas Oncology - DFW — Arlington, Texas
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in Texas: - The University of Texas, MD Anderson Cancer Center - Woodlands — Conroe, Texas
- Renovatio Clinical - El Paso — El Paso, Texas
- The University of Texas MD Anderson Cancer Center Diagnostic Imaging — Houston, Texas
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services — Houston, Texas
- The University of Texas, MD Anderson Cancer Center- Interventional Radiology — Houston, Texas
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Texas: - Research Site — Fort Worth, Texas
- Research Site — Houston, Texas
- Research Site — Kingwood, Texas
- Research Site — Lubbock, Texas
- Research Site — Round Rock, Texas
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Texas: - The Don and Sybil Harrington Cancer Center — Amarillo, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Texas: - Research Site — Fort Worth, Texas
- Research Site — Houston, Texas
- Research Site — Houston, Texas
- Research Site — Houston, Texas
- Research Site — Kingwood, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in Texas: - The University of Texas Southwestern Medical Center at Dallas — Dallas, Texas
- Renovatio Clinical - El Paso — El Paso, Texas
- JPS Health Network — Fort Worth, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Community Clinical Trials — Kingwood, Texas
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …
Sponsor: Pfizer
NCT ID: NCT07226999
Sites in Texas: - Texas Oncology - Northeast Texas — Allen, Texas
- Texas Oncology - DFW — Arlington, Texas
- Texas Oncology - DFW — Arlington, Texas
- Texas Oncology - Gulf Coast — Beaumont, Texas
- Texas Oncology - DFW — Bedford, Texas
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Texas: - Millennium Research and Clinical Development, LLC — Houston, Texas
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Texas: - Texas Oncology - DFW ( Site 8103) — Dallas, Texas
- UT Southwestern Medical Center ( Site 0190) — Dallas, Texas
- Houston Methodist Cancer Center ( Site 0191) — Houston, Texas
- MD Anderson Cancer Center ( Site 0150) — Houston, Texas
- Memorial Hermann Cancer Center ( Site 0172) — Houston, Texas
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Texas: - Texas Oncology Sammons Cancer Center — Dallas, Texas
- Local Institution - 0692 — Galveston, Texas
- Local Institution - 0652 — Laredo, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
- Texas Oncology - Northeast Texas — Tyler, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Texas: - University Of Texas Medical Branch At Galveston — Galveston, Texas
- Kelsey-Seybold Clinic Main Campus — Houston, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
- Local Institution - 0381 — San Antonio, Texas
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Texas: - Cardiothoracic and Vascular Surgeons — Austin, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Texas: - Research Site — Round Rock, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in Texas: - Texas Oncology - Central South — Austin, Texas
- University of Texas Southwestern Medical Center/Clinical Research Department — Dallas, Texas
- Texas Oncology - West Texas — Odessa, Texas
Phase 3 Recruiting Industry
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT07365241
Sites in Texas: - The University of Texas MD Anderson Cancer Center /ID# 280070 — Houston, Texas
- Texas Oncology - Northeast Texas /ID# 280642 — Tyler, Texas
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in Texas: - Old Parkland Hospital Hematology Oncology Clinic — Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas
- DHR Health Oncology Institute — Edinburg, Texas
- Houston Methodist Cancer Center — Houston, Texas
- Methodist Richardson Cancer Center — Richardson, Texas
Phase 3 Recruiting Industry
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Sponsor: Daiichi Sankyo
NCT ID: NCT06203210
Sites in Texas: - Houston Methodist Cancer Center — Houston, Texas
- University of Texas Md Anderson Cancer Center — Houston, Texas
- Texas Oncology, P.A. - Tyler — Tyler, Texas
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Texas: - Local Institution - 0025 — Houston, Texas
- Local Institution - 0173 — San Antonio, Texas
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Texas: - Hendrick Health — Abilene, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in Texas: - University of Texas M. D. Anderson Cancer Center — Houston, Texas
- Lumi Research — Kingwood, Texas
Phase 3 Recruiting Industry
This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …
Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in Texas: - University of Texas, MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07410117
Sites in Texas: - El Paso Medical Research Institute (Medresearch Inc) — El Paso, Texas
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas